MARKET

AFMD

AFMD

Affimed
NASDAQ
1.165
-0.015
-1.27%
Opening 11:13 02/07 EST
OPEN
1.190
PREV CLOSE
1.180
HIGH
1.200
LOW
1.140
VOLUME
356.62K
TURNOVER
200.73K
52 WEEK HIGH
5.10
52 WEEK LOW
1.030
MARKET CAP
170.00M
P/E (TTM)
-2.1010
1D
5D
1M
3M
1Y
5Y
SOFI, CVAC and AFMD are among pre market gainers
Seeking Alpha · 01/30 13:25
BRIEF-Affimed Provides Regulatory Update For AFM13
Reuters · 01/09 12:22
BRIEF-Affimed Announces Approval Of Clinical Trial Application In France For A Phase 1 Study Of AFM28
Reuters · 12/22/2022 13:52
Affimed Announces Approval Of Clinical Trial Application In France For A Phase 1 Study Of AFM28 In Relapsed/Refractory Acute Myeloid Leukemia
Benzinga · 12/22/2022 11:32
Affimed Says French Regulator Approves Clinical Trial Application for AFM28 for Relapsed/Refractory Acute Myeloid Leukemia
Affimed Says French Regulator Approves Clinical Trial Application for AFM28 for Relapsed/Refractory Acute Myeloid Leukemia
MT Newswires · 12/22/2022 07:38
Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential tre...
Zacks · 12/16/2022 14:35
Dow Surges Over 250 Points; Weber Shares Spike Higher
Benzinga · 12/12/2022 19:30
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 12/12/2022 18:05
More
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.